Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Donor-derived cell-free DNA (dd-cfDNA) is a marker of allograft injury in transplant recipients; however, the relationship between dd-cfDNA and other clinical parameters associated with adverse allograft outcomes is not well-characterized.
Methods: We performed a retrospective analysis of kidney transplant recipients from the DART cohort (ClinicalTrials.gov Identifier: NCT02424227) to evaluate the associations between eGFR decline, de novo donor-specific antibodies (dnDSA), and dd-cfDNA.
Results: Both elevated dd-cfDNA (≥1%) and dd-cfDNA variability (≥.34%) in the first post-transplant year were associated with decline in eGFR ≥25% in the second year (21.4% vs. 4.1%, P = .005; 25% vs. 3.6%, P = .002, respectively). Compared to samples from DSA negative patients, samples from patients with concurrent de novo HLA DSAs had higher dd-cfDNA levels (P < .0001).
Discussion: Abnormalities in dd-cfDNA levels are associated with clinical parameters commonly used as surrogate endpoints for adverse allograft outcomes, raising the possibility that molecular injury as characterized by dd-cfDNA could help identify patients at risk of these outcomes.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ctr.14402 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Donor-derived cell-free DNA in solid organ transplantation: analytical considerations, diagnostic performance, and clinical interpretation.
Clin Transplant Res
September 2025
Department of Laboratory Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Donor-derived cell-free DNA (dd-cfDNA) has emerged as a valuable noninvasive biomarker for detecting allograft injury in solid organ transplantation. It is released into the bloodstream from the transplanted organ as a result of cell injury and immune activation, with baseline levels influenced by organ type, tissue turnover, and posttransplant physiological changes. Several analytical platforms are available, including quantitative polymerase chain reaction (PCR), digital droplet PCR, and next-generation sequencing, each differing in sensitivity, throughput, and reporting format.
View Article and Find Full Text PDFDiagnostic approach to elevated dd-cfDNA with reassuring EMB in heart transplantation.
Front Transplant
August 2025
Department of Cardiovascular Disease, Inova Schar Heart and Vascular, Falls Church, VA, United States.
Despite significant advances in organ preservation, surgical techniques, and immunosuppressive regimens, rejection continues to pose a major challenge in the care of heart transplant patients. Endomyocardial biopsy (EMB) remains the gold standard test for surveillance and diagnosis of rejection, but is limited by its invasiveness, interobserver variability, procedural risk, and cost thus prompting the widespread use of non-invasive biomarkers such as donor-derived cell-free DNA (dd-cfDNA). Due to its high negative predictive value, dd-cfDNA is often routinely used for surveillance of asymptomatic patients.
View Article and Find Full Text PDFA Prospective Pilot Study to Investigate Whether Donor-Derived Cell-Free DNA Can Be Used as a Biomarker of Recurrent IgA Nephropathy Post-Kidney Transplantation.
Int J Immunogenet
August 2025
Transplant Laboratory, University Hospitals of Leicester, Leicester, UK.
IgA nephropathy (IgAN) is one of the most prevalent glomerulonephropathies and commonly leads to kidney failure. The recurrence of IgAN following transplantation remains a significant concern. Currently, detecting IgAN recurrence requires a kidney biopsy, highlighting the need for non-invasive biomarkers such as donor-derived cell-free DNA (dd-cfDNA) to aid in early detection.
View Article and Find Full Text PDFDonor-Derived Cell-Free DNA as a Marker for the Efficacy of Daratumumab in Patients With Antibody-Mediated Rejection Post-Heart Transplantation: A Case Series.
Pediatr Transplant
September 2025
University of Michigan, Ann Arbor, Michigan, USA.
Background: Antibody-mediated rejection (AMR) remains a significant complication following heart transplantation, contributing to graft dysfunction and reduced survival. Donor-derived cell-free DNA (dd-cfDNA) is emerging as a non-invasive biomarker for detecting and monitoring graft injury, correlating with episodes of rejection and response to treatment. Daratumumab, an anti-CD38 monoclonal antibody targeting plasma cells, has shown promise in treating AMR.
View Article and Find Full Text PDFDonor-derived cell-free DNA (dd-cfDNA) is a biomarker that enables the early detection of immune-mediated graft injury. This study evaluated the clinical utility of dd-cfDNA in predicting the presence of biopsy-proven rejection (BPAR). We analyzed 1,070 biopsies from 1,743 kidney transplant recipients enrolled in the prospective, multicenter Kidney Allograft Outcomes AlloSure Registry (KOAR).
View Article and Find Full Text PDF